KPN, APG To Form Dutch Joint Venture For Fiber Rollout

Dutch mobile telecommunications company Royal KPN N.V. (KKPNY.PK,KPN) said on Tuesday that it has reached an agreement with pension investor APG Group to form a joint venture, which will speed up the process of rollout of fiber and faster digitalization across the Netherlands.

As per the deal, APG will pay around 440 million euros on a pre-tax basis for a 50 percent stake in the joint venture. This will be split into an initial payment of 220 million euros and the remaining 220 million euros to paid in yearly instalments, depending on the progress of the rollout. The joint venture has a total equity value of 880 million euros.

During the rollout period, the capex of the joint venture will be around 1.2 billion euros, financed with 70 percent debt on a non-recourse basis. The initial payment will cover KPN's portion of expected equity contributions in the joint venture.

The deal is now subject to regulatory approval and the joint venture will begin operations in the second quarter of the year.

With this joint venture, KPN plans to increase its service revenues and make its presence felt in thinly populated areas in Netherlands. KPN has the potential to obtain, control and reconsolidate in the future.

In Netherlands, KPN shares were trading at 2.774 euros, down 4.3 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Southwest Airlines' flights across the United States were delayed for hours on Monday evening due to technical issue in a weather information system by a third-party weather data provider. The airline later resumed flight operations after solving the issue, but there were delays. The United Kingdom's Competition and Markets Authority or CMA announced Tuesday that it has launched a market study into mobile ecosystems of technology giants Apple Inc. (AAPL) and Google, Inc. (GOOG) over concerns they have market power which is harming users and other businesses. The CMA is taking... Eli Lilly and Co. (LLY) announced Tuesday that it will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant), an orally disintegrating tablet patients take every other day. This study will help to advance the science of migraine treatment...
Follow RTT